Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?

Soft tissue and bone sarcomas are a very heterogeneous group of tumors with many subtypes for which diagnosis and treatment remains a very challenging task. On top of that, the treatment choices are limited, and the prognosis of aggressive sarcomas remains poor. Immune checkpoint inhibitors (ICIs) h...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-01, Vol.13 (2), p.360
Main Authors: Siozopoulou, Vasiliki, Domen, Andreas, Zwaenepoel, Karen, Van Beeck, Annelies, Smits, Evelien, Pauwels, Patrick, Marcq, Elly
Format: Article
Language:English
Subjects:
Biomarkers
Bone cancer
Bone tumors
Cancer therapies
Chemotherapy
Clinical medicine
Clinical trials
Ewings sarcoma
Hodgkin's lymphoma
Immune checkpoint inhibitors
Immune system
Immunosuppressive agents
Immunotherapy
Kinases
Lung carcinoma
Medical prognosis
Melanoma
Metastasis
Mutation
Non-small cell lung carcinoma
Patients
Review
Sarcoma
Small cell lung carcinoma
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soft tissue and bone sarcomas are a very heterogeneous group of tumors with many subtypes for which diagnosis and treatment remains a very challenging task. On top of that, the treatment choices are limited, and the prognosis of aggressive sarcomas remains poor. Immune checkpoint inhibitors (ICIs) have drawn a lot of attention last years because of their promising response rates and their durable effects. ICIs are currently widely used in the daily routine practice for the treatment of a different malignancies, such as melanoma, Hodgkin lymphoma, and non-small cell lung carcinoma. Still, ICIs are not included in the standard treatment protocols of the different sarcoma types. However, a plethora of clinical trials investigates the clinical benefit of ICIs in sarcomas. There is clear need to develop predictive biomarkers to determine which sarcoma patients are most likely to benefit from immune checkpoint blockade. This review will focus on (i) the clinical trial results on the use of ICIs in different sarcoma types; and on (ii) possible biomarkers predictive for the effectiveness of these drugs in sarcomas.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13020360